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INTRODUCTION
Graft-vs.-host disease (GVHD) is the major life-threat-
ening complication of allogeneic bone marrow transplanta-
tion (BMT). Cyclosporine alone or combinations of cyclo-
sporine with methotrexate or corticosteroids have emerged
as effective preventive strategies for acute GVHD [1–13].
Notwithstanding, GVHD remains a significant cause of
morbidity and mortality in patients undergoing allogeneic
BMT [14]. Accordingly, the search for new and more effec-
tive immunosuppressive regimens has continued.
Tacrolimus (FK506) is a macrolide lactone produced by
Streptomyces tsukubaensis which has been noted to be highly
immunosuppressive in in vitro assays [15]. Although struc-
turally the binding domain of the tacrolimus molecule
appears similar to rapamycin and dissimilar to cyclosporine A
(CsA), its activity resembles that of CsA more than that of
rapamycin. Like CsA, tacrolimus forms a complex with an
immunophilin (FK binding protein in the case of FK506 and
cyclophilin in the case of CsA), which then interferes with the
phosphatase activity of calcineurin [16]. These complexes
inhibit the transcriptional activity of nuclear factor of activat-
ed T cells (NF-AT) and in turn interleukin-2 production. In
clinical use, tacrolimus appears to be highly active in prevent-
ing allograft rejection [17–19]. In preclinical animal models of
Relationship of tacrolimus (FK506) whole blood
concentrations and efficacy and safety after HLA-
identical sibling bone marrow transplantation
John R. Wingard,1 Richard A. Nash,2 Donna Przepiorka,3 Jared L. Klein,4 Daniel J. Weisdorf,5
Joseph W. Fay,6 Jin Zhu,7 Rochelle M. Maher,7 William E. Fitzsimmons,7 Voravit Ratanatharathorn8
1University of Florida College of Medicine, Gainesville, FL; 2Fred Hutchinson Cancer Research Center, Seattle, WA;
3MD Anderson Cancer Center, Houston, TX; 4Ohio State University, Columbus, OH; 5University of Minnesota, Min-
neapolis, MN; 6Baylor University Medical Center, Dallas, TX; 7Fujisawa USA, Deerfield, IL; 8Wayne State University,
Detroit, MI
Offprint requests: John R. Wingard, MD, Bone Marrow Transplant Program, University of Florida College of Medicine,
Department of Medicine, Division of Hematology/Oncology, PO Box 100277, JHMHC, Gainesville, FL 32610-0277
(Received 5 June 1998; accepted 8 September 1998)
ABSTRACT
A randomized clinical trial comparing tacrolimus with cyclosporine, both with short-course methotrexate, as prophy-
laxis against graft-vs.-host disease (GVHD) in allogeneic HLA-matched sibling bone marrow transplant patients was
conducted. Cyclosporine was dosed to achieve a target concentration range between 150 and 450 ng/mL during the
first 8 weeks after transplant. For tacrolimus, the target concentration range was 10–30 ng/mL during the first 8
weeks after transplant. A gradual tapering schedule of 20% per month during months 3–6 was then conducted for
patients in both treatment arms. The efficacy of the immunosuppressive regimen was determined by the rate of acute
GVHD grades II–IV. The toxicity of the immunosuppressive regimen was determined by the occurrence of the crea-
tinine exceeding 2 mg/dL, the creatinine doubling the baseline value, or the necessity for hemodialysis. Correlations
between blood concentrations and efficacy and toxicity parameters were assessed. For both tacrolimus and cyclo-
sporine, increasing blood concentrations were associated with greater renal dysfunction. For cyclosporine, there was
a nonsignificant trend to an increased incidence of grades II–IV acute GVHD with lower cyclosporine blood concen-
trations (300 ng/mL). In contrast, there did not appear to be a relationship between the blood concentrations of
tacrolimus and the occurrence of acute GVHD. This suggests that optimization of efficacy while minimizing the risk
for nephrotoxicity could be achieved by dosing tacrolimus to a targeted range between 10 and 20 ng/mL.
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marrow transplantation, tacrolimus was effective as prophy-
laxis and therapy for GVHD [20–22]. Several phase II trials
have shown tacrolimus either alone or in combination with
short-course methotrexate or methylprednisolone is efﬁca-
cious in human marrow transplantation [23–26]. In a ran-
domized trial comparing cyclosporine plus methotrexate vs.
tacrolimus plus methotrexate [27], increased efficacy was
noted in patients who received tacrolimus plus methotrexate.
There is considerable interpatient variability of absorp-
tion and metabolism of cyclosporine [28]. The pharmacoki-
netics are influenced by a variety of factors which include
the presence of enteritis from chemoradiation or acute
GVHD, age, plasma lipoprotein concentrations, the pres-
ence of hepatic or renal dysfunction, erythrocyte mass, the
concomitant ingestion of food, milk, or fruit juices, and a
variety of drug interactions [29–35]. Several studies have
suggested a correlation of cyclosporine toxicity with blood
concentrations [36–43]. The association of efficacy with
cyclosporine blood concentrations has been less clear
[3,36–38,44,45]. There are limited data on the association of
tacrolimus with either efﬁcacy or toxicity in bone marrow
transplant patients. Data accumulated from solid organ
transplant patients suggest that there is an association of
blood concentrations with toxicity [46].
In this study, we assessed the association of blood con-
centrations of cyclosporine and tacrolimus with safety and
efﬁcacy in a subgroup of patients entered into a randomized
controlled trial comparing these two immunosuppressive
agents in combination with a short course of methotrexate
as prophylaxis against acute GVHD.
METHODS
Patients
The participants of this study were patients entered into
an open-label prospective randomized multicenter study of
recipients of allogeneic HLA-matched sibling bone marrow
transplants. Treatment assignment was stratiﬁed by patient
age (40 years old vs. 40 years old) and alloimmunized
female donor to male recipient or not.
All patients were 12 years of age, and the donor and
patient were genotypically HLA-identical. Patients had to
have a creatinine of 3.0 mg/dL and could not have
received a T cell-depleted marrow graft or undergone a
prior transplant.
Immunosuppressive regimens
Individuals randomized to the tacrolimus regimen
received tacrolimus at a dose of 0.03 mg/kg/day as a contin-
uous intravenous infusion beginning on the day before
transplant. Once they could reliably receive oral medica-
tions, they were switched to an oral dose 4 times greater
than the intravenous dose, which was given in two divided
doses every 12 hours.
Individuals randomized to the cyclosporine regimen
received a dose of 3.0 mg/kg/day as a continuous intravenous
infusion beginning on the day before transplant, and, once
patients were able to take oral medications reliably, this dose
was switched to an oral dose 4 times greater than the intra-
venous dose given in two divided doses every 12 hours. Both
tacrolimus and cyclosporine doses were calculated using lean
body weights. All patients received methotrexate on day 1 at
a dose of 15 mg/m2 intravenously. On days 3, 6, and 11, they
also intravenously received 10 mg/m2.
Doses of both tacrolimus and cyclosporine were tapered
beginning week 9 if GVHD had not occurred. Each month
the dose was reduced by 20% of the week 8 dose. The
monthly tapering schedule continued for 6 months, when
the patient was discontinued from the randomized therapy.
The dose tapering was delayed in patients with GVHD until
clinically feasible. Before week 9, doses were adjusted either
because of levels outside of the targeted range or based on
intolerance. If the levels were low during the ﬁrst 8 weeks
posttransplant, the dose was increased by 10–25%. If the
tacrolimus level ranged between 31 and 40 ng/mL, a dose
reduction of 0–25% was performed according to the clini-
cian’s discretion; if it ranged between 41 and 50 ng/mL, a
dose reduction of 25–50% was made; and if it exceeded 50
ng/mL, the dose was held for 12 hours and then decreased
by 50%. For cyclosporine, if the level ranged between 451
and 600 ng/mL, the dose was reduced 0–25%; if the level
was between 601 and 750 ng/mL, the dose was decreased
25–50%; and if the level exceeded 750 ng/mL, the dose was
held for 12 hours and then reduced by 50%.
Dose adjustments were also performed because of intol-
erance. Clinicians were given discretion as to the degree of
dose reduction based on the overall clinical status of the
patient and the occurrence of GVHD. The most prevalent
cause for dose reduction was a rise in creatinine. If the serum
creatinine rose between 1.25 and 1.5 times the baseline, the
dose of cyclosporine or tacrolimus was reduced between 0
and 25%. If the serum creatinine rose 1.5–2.0 times the
baseline, a dose reduction of 0–50% was made. If the serum
creatinine rose to 2.0–2.5 times the baseline, the dose was
reduced by 25–75%. If the serum creatinine rose to 2.5–
3.0 times the baseline, the dose was reduced by 25–100%. If
the serum creatinine rose 3 times the baseline or if the
patient required hemodialysis, the dose was reduced by
50–100%. Subsequently, the doses of tacrolimus and cyclo-
sporine could be increased following a dose reduction at the
discretion of the investigator. If doses were held, they could
be reinstituted if the patient’s condition improved. Both
cyclosporine and tacrolimus doses could be increased by
10–25% for patients with acute or chronic GVHD if they
were not experiencing evidence of intolerance. If the patient
experienced a grade II–IV adverse event that was considered
probably or deﬁnitely related to cyclosporine or tacrolimus
in systems other than renal function, doses were also reduced
depending on the severity and according to the grading sys-
tem of the Southwest Oncology Group (SWOG) toxicity
criteria. Doses of methotrexate were reduced also in accor-
dance with toxicities attributable to methotrexate as graded
by the grades II–IV SWOG toxicities of elevated creatinine,
hepatic function, stomatitis, other mucositis, or third spacing
edema, ascites, or weight gain.
Blood concentration monitoring
Tacrolimus whole blood concentrations were measured 3
times a week by whole blood IMx (Abbott, Chicago, IL) [47]
during the ﬁrst 3 weeks, then once a week during weeks 4–8,
and once a month until 6 months. Cyclosporine doses were
similarly monitored, and its whole blood levels were measured
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by high-performance liquid chromatography (HPLC) or
monoclonal immunoassay [48]. For tacrolimus, the target con-
centration range was 10–30 ng/mL. For cyclosporine, the tar-
get range was 150–450 ng/mL. Data from disparate cyclo-
sporine assays were not included, i.e., if the center used a poly-
clonal whole blood assay with a target therapeutic range of
300–900 ng/mL instead of a target range of 150–450 ng/mL,
the center’s data were not included in the analysis. Doses were
adjusted according to blood concentrations and toxicity.
Before day 25, most of the blood concentration levels
were steady-state levels (while the patient was receiving the
intravenous drug). Following day 25, most of the blood lev-
els were trough levels. These levels were similar for both
tacrolimus and cyclosporine.
Analysis
The event analyzed in terms of efﬁcacy was the occur-
rence of acute GVHD grade II–IV. In terms of safety, the
occurrence of a serum creatinine exceeding twice the baseline
value, the occurrence of a serum creatinine exceeding 2
mg/dL, and hemodialysis were assessed. The relationship of
these endpoints with the whole blood level was analyzed using
Cox models, where time to the efﬁcacy endpoint was censored
by death, relapse, and discontinuation, and time to the safety
endpoints was censored by death and discontinuation.
For each day and each patient who was still in the study,
the mean blood level of the previous 14 days was calculated.
Missing values were imputed by carrying the previous value
forward. This mean level was used as a continuous time-
dependent covariate in a Cox model to assess the risk of the
endpoints. Patients receiving tacrolimus were also
dichotomized in two groups at each day according to the
mean 14 day blood level as less than or greater than 20
ng/mL. Note that a patient could be in one group on one
day and in the other group on another. This dichotomous
variable was used as a discrete time-dependent covariate in a
Cox model to assess the risk ratio of tacrolimus blood levels
20 and 20. A similar analysis was performed with cyclo-
sporine using a cutoff of 300 ng/mL. When analyzing the
blood level relationships, individuals who had discontinued
therapy before the event would not have had blood levels of
the study drug in the time period just before the event.
Therefore, the GVHD endpoint was censored by discontin-
uation of the study drug, in addition to death or relapse.
Thus, the rates of GVHD and nephrotoxicity in this manu-
script are lower than that reported elsewhere [27].
For the purpose of visualization, logistic regression was
used to assess the relation of acute GVHD and creatinine
2 mg/dL and 2  baseline with the mean whole blood
level before an event or censor time. Incidence rates were
plotted against the mean blood level.
RESULTS
Patients
In Table 1 are listed characteristics of the patients
included in this study. Blood levels of tacrolimus and cyclo-
Table 1. Patient demographics
Tacrolimus Cyclosporine 
(n165) (n164) p
Age
Median (range) 40 (17–61) 40 (16–63) 0.99
Sex
Men 93 (56%) 100 (61%) 0.39
Women 72 (44%) 64 (39%)
Race
Caucasian 146 (89%) 135 (82%) 0.11
Other 19 (11%) 29 (18%)
CMV seropositive 105 (64%) 114 (70%) 0.29
Alloimmunized
Women ➝ men 35 (21%) 31 (19%) 0.60
Creatinine at
baseline (mg/dL) 0.80  0.26 0.81  0.27 0.62
Disease category
Advanceda 68 (41%) 48 (29%) 0.02
Non-advanced 97 (59%) 116 (71%)
aChronic myelogenous leukemia in blast crisis, chronic lymphocytic leukemia,
multiple myeloma, other malignancies not in remission.
Figure 1. Whole blood levels of tacrolimus at various time points
after transplant 
Before day 25, the blood concentration levels were steady-state levels; following
day 25, most of the blood levels were trough levels. Note that from 3 months
on, a gradual tapering schedule of 20% per month was conducted. Each data
point represents the mean  SEM.
Figure 2. Whole blood levels of cyclosporine at various time
points after transplant
Before day 25, most of the blood levels were steady state; after day 25, most were
trough levels. Note that from 3 months on, a tapering of cyclosporine by 20%
per month was conducted. Each data point represents the mean  SEM.
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sporine at different timepoints are indicated in Figures 1
and 2, respectively. The baseline creatinines were not
significantly different between the tacrolimus and cyclo-
sporine groups overall and also did not differ in the
advanced and non-advanced disease subgroups. The inci-
dence of grades II–IV acute GVHD was 37% in the cyclo-
sporine treatment arm and 22% in the tacrolimus arm (p 
0.003) (Table 2). An elevation in creatinine to greater than
twice the baseline occurred in 67 and 75%, respectively, in
the cyclosporine and tacrolimus groups (p  0.14). An ele-
vation in creatinine exceeding 2.0 mg/dL occurred in 48 and
57%, respectively, of the two treatment groups (p  0.088).
Hemodialysis was performed in 4 and 10%, respectively, in
the two treatment groups (p  0.035).
Association of blood concentrations and clinical events
In Tables 3 and 4 are the time-dependent analyses
assessing the association of the safety and efﬁcacy endpoints
with the blood concentrations of tacrolimus and cyclo-
sporine. The risk ratios are calculated as an incremental risk
ratio (the association of the event and the blood concentra-
tion, with the unit being 1 ng/mL for tacrolimus and 15
ng/mL for cyclosporine) (Table 3) or as a dichotomous risk
ratio, where concentrations were divided by the midpoint of
the target range (Table 4). For example, the risk for creati-
nine 2.0 mg/dL increases by 3.9% when the mean level of
tacrolimus over 14 days before the event increases by 1
ng/mL; the risk for patients with a tacrolimus level of 11
ng/mL is 3.9% greater than a patient whose level is 10
ng/mL (Table 3). For tacrolimus, the risk for creatinine 2
mg/dL increases by 84.4% when the mean level of
tacrolimus over 14 days before the event is 20 ng/mL
compared with a mean level of 20 ng/mL; for cyclo-
sporine, the risk for creatinine 2 times the baseline
increases by 94.1% when the mean level of cyclosporine
over 14 days before the event is 300 ng/mL compared
with a mean level of less than 300 ng/mL (Table 4). An
analysis using a 7-day window between the blood level and
endpoint instead of the 14 days before each event showed
similar results (data not shown).
The relationship of tacrolimus blood levels with the efﬁ-
cacy and toxicity parameters using the logistic regression
model data is depicted in Figure 3. The relationship
between cyclosporine levels and efﬁcacy and toxicity param-
eters is depicted in Figure 4. These data suggest that there is
no relationship between the blood concentrations of
tacrolimus and the occurrence of acute GVHD. In contrast,
with cyclosporine there is a nonsignificant trend for an
increased incidence of grades II–IV acute GVHD with
lower cyclosporine blood concentrations (300 ng/mL, p 
0.17). There was a relationship between the blood concen-
trations of both tacrolimus and cyclosporine with increasing
indices of nephrotoxicity.
DISCUSSION
The goals of the immunosuppressive regimen following
BMT are to promote engraftment, prevent GVHD, main-
tain the graft-vs.-tumor effect, allow the development of
robust immune responses to infectious pathogens, and facil-
itate the development of transplant tolerance. A variety of
immunosuppressive regimens have been evaluated over the
years. Various regimens have been more or less successful in
achieving these goals. The transplant clinician must be vigi-
lant in monitoring any given regimen’s efficacy over time,
while minimizing its toxicities.
Because of interpatient variability in absorption and
metabolism of immunosuppressive drugs and the dynamic
changes in gastrointestinal function in the early transplant
setting, pharmacologic monitoring was felt to be important
in the evaluation of cyclosporine and tacrolimus as GVHD
prophylaxis. The data in this trial demonstrate that, for both
tacrolimus and cyclosporine, increasing drug blood concen-
trations were associated with increasing risk of renal dysfunc-
tion. This observation was concordant with earlier studies
with cyclosporine used in the BMT setting [36–38,42,49].
In contrast, assessing the relationship between blood con-
centrations of immunosuppressive drugs and the control of
Table 2. Efﬁcacy and safety events
Events Tacrolimus Cyclosporine 
number (%) number (%) pa
Grade II–IV acute GVHD 36 (22%) 60 (37%) 0.003
Creatinine 2  baseline 123 (75%) 110 (67%) 0.14
Creatinine 2 mg/dL 94 (57%) 78 (48%) 0.088
Hemodialysis 17 (10%) 7 (4%) 0.035
aChi-square.
Table 3. Comparison of tacrolimus and cyclosporine blood levels with safety and efﬁcacy endpoints
Tacrolimus Cyclosporine
Incremental risk ratioa Incremental risk ratioa
n (%) (unit  1 ng/mL) p n (%) (unit  15 ng/mL) p
Grade II–IV acute GVHD 36 (22) 1.038 0.111 60 (37) 0.976 0.129
Creatinine 2  baselinea 123 (75) 1.024b 0.025 110 (67) 1.029c 0.002
Creatinine 2 mg/dL 94 (57) 1.039 0.001 78 (48) 1.013 0.250
Dialysis 17 (10) 1.058 0.057 7 (4) 0.922 0.130
When p  0.05, the risk for an event is interpreted as: (risk ratio – 1)  100.
aFrom the Cox model.
bExample: The risk for creatinine 2  baseline increases by 2.4% when the mean tacrolimus level over 14 days before the event increases by 1 ng/mL.
cExample: The risk for creatinine 2  baseline increases by 2.9% when the mean cyclosporine level over 14 days before the event increases by 15 ng/mL.
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GVHD have been less deﬁnitive. Many studies have failed to
show a significant association between cyclosporine blood
concentrations and the occurrence of acute GVHD [44]. Sev-
eral studies, however, have demonstrated the correlation
between lower drug concentrations and higher rates of acute
GVHD [3,37,38,45,50]. In this clinical trial, increasing cyclo-
sporine levels tended to be associated with a reduced risk of
acute GVHD, although this was a nonsigniﬁcant trend. In
contrast, however, no relationship between tacrolimus blood
levels and the occurrence of acute GVHD was seen. Accord-
ingly, it is reasonable to conclude that the maintenance of
tacrolimus blood levels between 10 and 20 ng/mL should
reduce the risk for renal dysfunction, without compromising
the efﬁcacy advantage over cyclosporine in reducing the rate
of acute GVHD. This is consistent with observations in solid
organ transplant recipients for whom the maintenance of
tacrolimus blood concentrations of between 5 and 15 was
associated with adequate immunosuppression without graft
rejection and low rates of nephrotoxicity [46]. Ultimately, it
would be desirable to incorporate a multitude of risk factors
for the occurrence of GVHD as well as renal dysfunction to
assist the clinician in deciding to target concentrations in the
lower therapeutic range for patients with a relatively low risk
of GVHD or with a high risk for renal dysfunction, and to
identify target individuals at high risk for GVHD or at low
risk for renal toxicity for higher targeted drug concentrations.
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